Extracellular single unit recording techniques were used to study the effects of both acute and repeated oral neuroleptic administration on the in vivo activity of rat A9 and A10 dopaminergic (DA) neurons. All antipsychotic drugs examined acutely (haloperidol, l-sulpiride, chlorpromazine, and clozapine) increased the number of spontaneously firing DA neurons in both A9 and A10 compared to controls. Repeated (21 day) treatment with haloperidol, I-sulpiride, and chlorpromazine (antipsychotic drugs which can cause extrapyramidal side effects) markedly reduced the number of active DA cells below control levels in both regions. The "silent" DA neurons were in an apparent state of tonic depolarization inactivation since they could be induced to discharge by the microiontophoretic application of the inhibitory neurotransmitter y-aminobutyric acid, but not the excitatory amino acid glutamate. The depolarization inactivation observed may be specific for antipsychotic drugs since a non-neuroleptic phenothiazine (promethazine), the inactive isomer of sulpiride (dsulpiride), and a tricyclic antidepressant (desmethylimipramine) neither increased DA activity when given acutely nor induced depolarization inactivation when administered repeatedly. In contrast to the other drugs tested, repeated treatment with clozapine (an effective antipsychotic drug which does not produce extrapyramidal side effects) resulted in the depolarization inactivation of A10 neurons but not A9 cells. These data suggest that neuroleptics which can induce extrapyramidal side effects produce depolarization inactivation of both A9 and A10 neurons whereas antipsychotic drugs which lack this property inactivate only A10 neurons. It is suggested that the time-dependent development of A9 DA neuron inactivation induced by repeated neuroleptic treatment may provide a mechanism for understanding the delayed onset of extrapyramidal side effects often observed with these drugs.
Drugs which have as their primary action the blockade of central dopamine receptors (i.e., neuroleptics) are widely accepted as being the therapeutic agents of choice for the treatment of the major symptoms of psychosis (Klein et al., 1980) . Unfortunately, neuroleptic treatment also can cause numerous side effects, including the often irreversible movement disorder tardive dyskinesia (Klawans, 1976; Klein et al., 1980; Jeste and Wyatt, 1982; Kane and Smith, 1982) . In man, many of the therapeutic ' actions and side effects of neuroleptics can take days to weeks, and in some cases months, to develop (Crane, 1973; Cotes et al., 1978; Beckman et al., 1979) . For this reason, basic research has turned increasingly toward an investigation of the effects of chronic neuroleptic treatment on neuronal systems. Such studies have often demonstrated marked differences between the effects of acute administration of a drug and the effects produced by repeated administration. For example, although it is well established that the biochemical consequence of acute dopamine (DA) receptor blockade is a compensatory increase in DA turnover (Carlsson and Linqvist, 1963; Nyback et al., 1967; Nyback and Sedvall, 1970; Anden and Stock, 1973; Hyttel, 1974; Roth et al., 1975; Wilk et al., 1975; Zivkovic et al., 1975; Wilk and Stanley, 1978; Meller et al., 1980; Bannon et al., 1983) , these effects are greatly diminished (i.e., tolerance develops) during repeated treatment with these compounds (Bowers and Rozitis, 1974; Scatton et al., 1975; Laduron et al., 1977; 1608 Chiodo and Bunney Vol. 3, No. 8, Aug. 1983 Lerner et al., 1977; Scatton, 1977 Scatton, , 1980 Meller et al., 1980; Wheeler and Roth, 1980; Bacopoulos et al., 1982; Bannon et al., 1982a) . A second example is provided by electrophysiological studies. Thus, acute neuroleptic administration increases (Bunney et al., 1973; Bunney and Grace, 1978; Bunney, 1979) , whereas repeated administration (21 days) decreases, the number of spontaneously active DA neurons located within the zona compacta region of the substantia nigra (Bunney and Grace, 1978) . In the latter case, the inactive DA cells could be induced to fire by the microiontophoretic application of the inhibitory neurotransmitter y-aminobutyric acid but not by the excitatory amino acid glutamate, suggesting that they were in a state of tonic depolarization inactivation.
In these early electrophysiological experiments, only DA neurons in the substantia nigra zone compacta (A9 area; Dahlstrom and Fuxe, 1964) were studied. However, when considering the actions of chronic neuroleptic administration on central DA neurons, it has become increasingly apparent that one needs to examine their effects upon several anatomically and/or functionally distinct DA systems. For example, it is generally accepted that the extrapyramidal side effects which accompany neuroleptic treatment are due primarily to their actions on the nigrostriatal DA system (Barbeau, 1969; Klawans and McKendall, 1971; Baldessarini and Tarsy, 1976, 1980; Sovner and DiMascio, 1978) . The cells of origin for this DA system are located within the A9 areas and terminate mainly within the caudate nucleus (Hokfelt et al., 1974; Bunney and Aghajanian, 1976; Lindvall and Bjorklund, 1978; Lindvall, 1979) . On the other hand, the antipsychotic properties of these compounds have been suggested to be mediated via their effects on mesolimbic and mesocortical DA systems (Snyder, 1972; Matthysse, 1973; Stevens, 1973; Hokfelt et al., 1974; Snyder et al., 1974; Glowinski, 1975; Meltzer and Stahl, 1976) . The cell bodies of these DA neurons are located predominantly within the ventral tegmental area (region A10 of Dahlstrom and Fuxe, 1964) and project mainly to the limbic and cortical regions (Berger et al., 1974 (Berger et al., , 1976 Berger, 1977; Lindvall et al., 1977; Lindvall and Bjorkland, 1978; Lindvall, 1979; Swanson, 1982) . In the present study we examined the effects of both acute and repeated (21 day) oral administration of a variety of neuroleptics on the spontaneous activity of DA neurons located in both the A9 and A10 regions. Haloperidol, chlorpromazine, and lsulpiride were studied because they represent three different chemical classes of neuroleptics which are both clinically effective and associated with the development of extrapyramidal side effects. Clozapine was tested because, although therapeutically active (Gerlach et al., 1974; Chouinard and Annable, 1976; Shopsin et al., 1979) , it has not been associated with the induction of these side effects (Gerlach et al., 1975) . For purposes of comparison, we also examined the effects, on DA cell activity, of acute and chronic treatment with the inactive isomer of sulpiride (d-sulpiride), the non-neuroleptic phenothiazine promethazine, and the antidepressant desmethylimipramine.
Materials and Methods
Animals and drug treatment. Male Sprague-Dawley albino rats (Charles-River), weighing 200 to 225 gm at the start of the experiment, were used throughout the study. They were housed two per cage and maintained on a controlled 12-hr light: 12-hr dark cycle, with free access to food and water. In the acute studies, animals were given one of the following drugs via intragastric intubation: haloperidol (HAL; 0.5 mg/kg), l-sulpiride (Z-SLP; 20 mg/kg), d-sulpiride (d-SLP; 20 mg/kg), chlorpromazine (CPZ; 5 mg/kg), clozapine (CLZ; 20 mg/kg), promethazine (PRO; 19 mg/kg), or desmethylimipramine (DMI; 10 mg/kg). In the chronic studies another group of animals was given these drugs in their drinking water for 21 consecutive days. When averaged over 21 days of treatment, the mean daily dose for each drug was: HAL: 0.56 + 0.08 mg/kg; l-SLP: 21.15 + 0.42 mg/kg; d-SLP: 19.99 f 0.40 mg/kg; CPZ: 5.56 + 0.08 mg/kg; CLZ: 24.45 f 0.74 mg/kg; PRO: 19.25 + 0.62 mg/kg; and DMI: 11.40 +0.23 mg/kg (Table I) . Untreated control animals were also sampled for the purpose of comparison. All chronically treated animals were weighed twice a week and the drugs placed in light-proof drinking bottles. No significant difference in weight gain was seen in any of the treatment groups. Daily water intakes were measured for each cage and the actual dose of drug the animals received was calculated from these values (see "Results"). All drug doses are expressed as the weight of their salt.
Electrophysiological methods. One hour after acute treatment, or on day 21 of repeated administration, a given animal was anesthetized with chloral hydrate (400 mg/kg, i.p.) and placed in a stereotaxic apparatus. In all cases the experimenter was blind with respect to the After reflecting the scalp, the skull overlying both the substantia nigra (A9; anterior 1,750 to 2,580 pm, lateral 2,100 to 1,700 pm, Konig and Klippel, 1974) and the ventral tegmental area (AlO; anterior 1,610 to 2,420 pm, lateral 100 to 500 pm) was removed. Extracellular neuronal signals were sampled using a single barrel micropipette (overall tip diameter less than 1 pm) filled with 2 M NaCl containing 2% pontamine sky blue dye (in vitro impedance measured at 135 Hz, 4 to 8 megohms). These signals were passed to a high input impedance amplifier (bandpass settings: 120 Hz to 3 kHz) whose output was led to an oscilloscope and audio monitor. Firing rates were calculated on-line by a rate-averaging computer. Spontaneously firing DA cells within both the A9 and A10 regions were counted by lowering the electrode through a block of tissue (120,000 pm', Fig. 1 ) which could be reproducibly located from animal to animal. Twelve electrode tracks (separated from each other by 200 pm), whose sequence was kept constant from animal to animal, were made in each region. Only cells whose electrophysiological characteristics matched those previously established for midbrain DA-containing neurons (Bunney et al., 1973; Grace and Bunney, 1980, 1983a, b) were sampled. In the microiontrophoretic experiments five-barrel micropipettes (overall tip diameter 4 to 7 ym) were employed as previously described (Aghajanian and Bunney, 1977) . The center barrel was filled with 2 M NaCl containing 2% pontamine sky blue dye (in vitro impedance AI0 SNR A 2420JJm at 135 Hz, 4 to 8 megohms). One of the side barrels was filled with 3 M NaCl and was used for the automatic neutralization of tip currents (Salmoraghi and Weight, 1967) . The other three outer barrels were filled with either y-aminobutyric acid (GABA; 0.05 M, pH 4.0, Sigma) or glutamic acid (GLU; 0.01 M in 0.01 M NaCl, pH 8.0, Sigma). A retaining current of 10 nA was used to eliminate the passive diffusion of drug.
In some studies cells were identified according to their area of projection by antidromic activation from the region they innervated. In these experiments concentric bipolar electrodes (SNE-100, David Kopf Instruments) were stereotaxically placed in the region of the prefrontal cortex (anterior 9,650 to 11,050, lateral 200 to 1,000; Konig and Klippel, 1974) . Constant current (0.3 to 3.0 mA) square wave pulses of 500-psec duration were employed. Neurons were considered antidromically activated when the following criteria were met: (1) one antidromic spike per stimulation, (2) a fixed latency for the stimulus-induced action potential, (3) stimulation rates of 100 Hz could be followed by the antidromically driven cell, and (4) collision was observed between spontaneously occurring action potentials and the antidromic spike.
Recording sites were marked by passing a -30 PA current through the recording barrel for 10 min which resulted in the ejection of a 50-pm diameter spot of blue dye. The rats were perfused with a phosphate-buffered 10% formalin solution, and the brain was removed. Serial frozen sections were cut at 50-pm intervals and stained with a formal-thionin solution (Donovick, 1974) . A light A9 A 2580pm Figure 1 . Schematic drawing (modified from Konig and Klippel, 1974) showing the location of the stereotaxically defined blocks of tissue within A9 and A10 in which all electrode tracks were made. SNR, substantia nigra, zona reticulata; mp, nucleus mammilaris posterior; ip, nucleus interpeduncularis. 1610 Chiodo and Bunney Vol. 3, No. 8, Aug. 1983 microscope was then used to locate each spot of ejected phenothiazine, PRO, the inactive isomer of sulpiride, ddye. Histological examination verified that all of the SLP, or the tricyclic antidepressant, DMI, had no effect electrode tracks placed in the present series of experion the number of DA neurons observed in A9 or AlO. ments were located within the blocks of tissue defined as In contrast to these acute effects, animals repeatedly A9 and A10 in Figure 1 . treated for 21 days with HAL, CPZ, or l-SLP had markOverall statistical significance between groups was edly fewer active DA neurons in A9 and A10 when determined by an analysis of variance. Post-hoc paired compared to untreated controls (Fig. 2) . For example, in comparisons of individual group differences were con-the HAL-treated animals we observed only 0.19 and 0.16 ducted'using the Dunnett test (two-tailed t statistic).
cells/track in A9 and AlO, respectively. Repeated CLZ Results treatment, on the other hand, had a strikingly different effect upon A9 and A10 DA neurons (Fig. 2) . Whereas a In the untreated control animals the mean number of marked reduction in the number of cells in A10 was DA neurons encountered in the A9 and A10 regions was observed (0.25 compared to 0.86 cells/track in control 0.81 and 0.86 cells/track, respectively (Fig. 2) . The av-animals), there was an irw-eased number of spontaerage spontaneous firing rate of the cells sampled was neously firing DA neurons in A9 (1.59 compared to 0.81 4.1 and 4.6 spikes/set, respectively. In contrast, the acute cells/track in controls). administration of each of the antipsychotic drugs tested
The repeated administration of the non-neuroleptic (I-SLP, HAL, CPZ, and CLZ) produced a 2-to 3-fold phenothiazine, PRO, and the inactive isomer of sulpiride, increase in the number of cells per track in both A9 and d-SLP, had no effect on either the number of A9 or A10 AlO. However, acute treatment with the non-neuroleptic cells encountered or their spontaneous activity (Fig. 2 ). Chronic treatment with the antidepressant DMI, which is not a DA receptor antagonist and does not produce extrapyramidal side effects when given chronically, significantly increased the number of neurons seen in both A9 and A10 (1.42 and 1.66 cells/track, respectively; Fig.  2) .
Previous work has demonstrated that the neurochemical (kainic acid) destruction of striatonigral and pallidonigral feedback pathways prior to repeated HAL administration prevents the induction of depolarization block (Bunney and Grace, 1978) . Given this observation,
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Figure 3. Schematic drawing (modified from Konig and Klippel, 1974) showing the region of transection (shaded area) for the animals represented in Figure 4 .
Part of the initial evidence indicating that the inactive A9 DA neurons were in fact in a state of depolarization block arose from the observation that these cells could be induced to fire by the microiontophoretic application of the inhibitory neurotransmitters GABA and DA, but not the excitatory amino acid GLU (Bunney and Grace, 1978) . We used the same experimental approach to determine if A10 DA neurons were also not firing due to an apparent depolarization inactivation. In chronically A9 AI0
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we examined the effects of acute hemitransection of the forebrain (immediately prior to recording) on the number of active DA neurons present in chronically CPZ-treated animals (6 of the 10 animals represented in Fig. 2) . In half the animals, active DA cells were counted on one side of the brain and immediately thereafter a glass microknife was stereotaxically lowered into the opposite hemisphere (at the level of the tail of the caudateputamen (anterior 4230 to 4620 pm; Konig and Klippel, 1974) , and the diencephalon was totally transected (Fig.  3 ). Recordings were immediately made from the A9 and A10 regions of the transected side. In the other three animals the knife cut was made first and the lesioned side was sampled before the intact side. As shown in Figure 4 , the transection reversed the depolarization inactivation normally produced by CPZ in A9 neurons while not changing the chronic effects of this drug in A10 neurons. In fact, knife cuts significantly elevated the number of A9 DA cells/track compared to unlesioned untreated animals (post-transection: 1.72 cells/track compared to 0.81 cells/track in control animals). In untreated animals, knife cuts did not alter the cells/tract in either A9 or Al0 (N = 4). Average firing rates were not different in these two conditions and were similar to control values. CPZ-treated animals multiple electrode passes were made through the zona compacta (number of animals, N = 10) while GABA was being pulsed from the pipette. Low ejection currents (1 to 5 nA) caused the onset and subsequent emergence of DA neuronal activity (identified by their electrophysiological characteristics) from the background noise (Fig. 5) . At first these GABAactivated neurons were firing rapidly and displayed relatively small amplitude action potentials. As the GABA application continued, the discharge rate slowed (i.e., interspike interval increased) and the action potential amplitude increased. If GABA iontophoresis was immediately discontinued these cells would then increase in rate while decreasing in amplitude until no longer discernible above the noise. When GABA iontophoresis was continued for approximately 30 to 60 set, these activated DA neurons would continue to discharge spontaneously in a normal manner (e.g., display normal bursting patterns). Further application of GABA at higher ejection currents totally inhibited DA activity. The extracellular Vol. 3, No. 8, Aug. 1983 action potentials observed for these GABA-activated silent DA neurons were identical to those previously reported for midbrain DA neurons (Bunney et al., 1973; Guyenet and Aghajanian, 1978; Bunney, 1979; Grace and Bunney, 1980; see Fig. 6C ). The subsequent local application of GLU (10 to 20 nA) onto "silent" DA neurons, which had been previously identified by transient GABA activation, did not induce cell firing in any of the cells tested ( Fig. 5; N = 12 ). This ability of locally applied GABA to induce activity in nonfiring DA cells was observed for both A9 (N = 12) and A10 (N = 24) neurons. In a similar fashion we were able to induce inactive A10 DA cells to fire with GABA, but not GLU, in animals repeatedly treated with HAL (N = 10; Fig. 5 ). In control animals, the microiontophoretic application of GABA and GLU at the concentrations and currents used in the present study exerted their normal respective inhibitory and excititory effects on DA neuron activity.
In the animals chronically treated with neuroleptics, we consistently observed a small group of spontaneously active A10 DA neurons which apparently did not develop depolarization block. These neurons had firing characteristics (6 to 10 spikes/set, with very intense bursting) similar to previously identified A10 DA neurons which project to the prefrontal cortex and which have been shown to be devoid of both nerve terminal and somatic/ dendritic autoreceptors (Bannon et al., 1981 (Bannon et al., , 1982b . To determine if the spontaneously firing A10 DA neurons observed in our chronically treated animals were in fact the same subpopulation of DA cells, attempts were made to antidromically activate them by means of prefrontal cortex stimulation. Of 10 neurons tested in HAL-treated animals, 8 met criteria for antidromic activation from the prefrontal cortex (Fig. 6 ). These antidromically activated neurons had fixed conduction latencies of 18.9 to 22.8 msec (mean f SEM, 20.5 + 0.7). For straight-line distances between the stimulating and recording electrode of 8.9 to 11.0 mm, these values correspond to an estimated conduction velocity of 0.47 to 0.58 m/set. This is similar to values previously reported for DA neurons (Deniau et al., 1978; Guyenet and Aghjanian, 1978; Grace and Bunney, 1980; Chiodo, 1981; Wang, 1981) .
A. A, This cell was activated by the microiontophoretic application of GABA (ejection current equals 3 nA). Note that after a short delay GABA causes the cell to appear out of the background noise. Continued application of GABA results in a decrease in activity (action potential amplitude increases and duration decreases). When the GABA is turned off, the rate of the cell markedly increases (action potential amplitude decreases and duration markedly increases) and the spikes disappear back into the noise. (The changes in spike duration are not visible due to the paper speed employed. These changes in action potential amplitude and duration are identical to those observed in untreated animals when the spontaneous activity of a DA cell increases or decreases (Bunney et al., 1973; Aghajanian and Bunney, 1977; Grace and Bunney, 1983a, b) . Under both conditions, due to the fact that dopamine cells can change from a slow irregular firing mode to a fast bursting mode with decreasing spike amplitudes within each burst, the spike height can vary enormously within a very short period of time (less than 100 msec). B, The lower truce shows that the excitatory amino acid GLU (ejected at 12 nA 1 min after the GABA ejection shown in the upper trace) was unable to activate the "silent" DA neuron. Horizontal bars represent the onset and duration of the iontophoretic drug application.
Calibration equals 400 p!J and 2 sec.
Discussion
Methodological considerations. Several difficulties are associated with the use of single unit extracellular electrophysiological techniques in studying the effects of repeated drug administration on brain neuronal activity. Presently available techniques do not allow us to record from the same individual cell for the entire 21 days of drug administration. Therefore, we must make comparisons between populations of DA neurons sampled in both control and drug-treated (acute or chronic) animals. As we have previously reported for A9 DA neurons (Bunney and Grace, 1978) , the probability of recording from the same population of DA cells in different animals is greatly increased by stereotaxically defining blocks of tissue within the zona compacta region and ventral tegmental area which can be reproducibly located in each animal. Since subsequent histology was conducted to ensure that all the electrode tracks made in our study were inside the confines of the stereotaxically defined (arrows; 1.9 mA, 500~psec duration) after a delay of 24.0 msec. This produces an antidromic spike (a, latency, 18.5 msec). The reduced amplitude of the antidromic spike compared to the spontaneous action potential is due to activation of only the initial segment component. B, Stimulation 21.5 msec after the spontaneous spike occurs fails to antidromically activate this cell, demonstrating that collision has occurred. Calibration = 200 pV, 10 msec. C, An individual action potential of a "silent" A10 DA neuron which has been activated by the microiontophoretic application of GABA (4 nA). Calibration = 100 pV, 2 msec. areas of A9 and A10 shown in Figure 1 , it would seem likely that comparisons were made between the same populations of cells in the different treatment groups.
Experimental
findings.
In our previous work we demonstrated that daily subcutaneous injections (21 days) of the butyrophenone neuroleptic HAL (0.5 mg/kg) resulted in a marked decrease in the number of spontaneously firing A9 DA neurons. More recently, a report by White and Wang (1983) has demonstrated that chronic HAL progressively reduces the number of active DA neurons in both A9 and AlO. The present study extends these earlier observations in several ways. First, we have shown that, regardless of structure (e.g., the butyrophenone HAL, the phenothiazine CPZ, the benzamide I-SLP, and the dibenzodiazepine CLZ), the acute administration of a neuroleptic will increase the number of active DA neurons in both A9 and AlO. Second, the daily oral administration of a variety of antipsychotic drugs, all of which produce neurological effects (i.e., HAL, CPZ, and I-SLP), decreases the number of spontaneously active DA neurons in both these regions. In agreement with earlier reports (Bunney and Grace, 1978; White and Wang, 1983) , the "silent" DA neurons observed in animals receiving neuroleptics chronically appear inactive due to excessive depolarization. This notion is supported by the fact that treatments which normally inhibit DA cell activity (systemic APO, iontophoretically applied DA or GABA) can induce silent cells to discharge in a normal fashion whereas excitatory agents (iontophoretically applied GLU) cannot induce activity (see Bunney and Grace, 1978; White and Wang, 1983) . However, since only extracellular recording data (which do not allow for the determination of the resting membrane potential) have been reported to date, the possibility that silent DA neurons are in a state of depolarization inactivation must still be considered tentative. Intracellular electrophysio- Vol. 3, No. 8, Aug. 1983 logical studies are currently under way to examine DA neurons in animals treated chronically with neuroleptics.
The above effects appear specific for neuroleptics since control compounds such as the non-neuroleptic phenothiazine, PRO, the inactive isomer of sulpiride, d-SLP, and the antidepressant, DMI, did not increase the number of DA neurons observed when administered acutely nor decrease the number of active DA cells in either brain region when given chronically (even at the relatively high doses we employed). Although DMI had no effect when given acutely, repeated administration did increase the number of active DA neurons in both A9 and AlO. This is in agreement with previous electrophysiological and biochemical findings demonstrating that repeated, but not acute, antidepressant administration alters the functioning of midbrain DA systems (Chiodo and Antelman, 1980; Serra et al., 1979 Serra et al., , 1981 Holcomb et al., 1982) .
A third extension of our earlier findings is the discovery that an ipsilateral hemisection between the striatum and substantia nigra, immediately prior to recording from chronically CPZ-treated animals, selectively reverses the observed inactivation of A9 neurons. This observation supports our previous finding (Bunney and Grace, 1978) that the feedback regulation normally provided by the striatonigral and pallidonigral pathways is critical for the expression of depolarization inactivation in A9. Together, these observations also suggest that the A9 neuron autoreceptor supersensitivity produced by chronic neuroleptics (Gallager et al., 1978; Bannon et al., 1980; Wheeler and Roth, 1980; Serra et al., 1981) is not a significant factor in the control of the firing rate of DA cells under these conditions. Theoretically, the development of supersensitive autoreceptors on DA cell bodies and dendrites would be expected to result in increased self-inhibition of DA neurons (Groves et al., 1975; Aghajanian and Bunney, 1977) and not depolarization.
When combined with our lesioning data, the fact that l-SLP, a putative selective D2-receptor antagonist (Kebabian and Calne, 1979; O'Conner and Brown, 1982) , was able to decrease the number of active DA neurons to the same extent as theother neuroleptics studied suggests that DP receptors on the long-loop striatonigral feedback pathways may be important for the induction and maintenance of depolarization inactivation. It is not known why acute hemitransections were unable to reverse the chronic CPZ-induced inactivation of A10 neurons. Since, as seen in Figure 3 , the knife cuts totally transected the midbrain from forebrain structures, this finding may suggest that mechanisms other than longloop feedback regulation from forebrain regions are involved in the depolarization inactivation of these DA neurons.
A fourth extension of our earlier work is the finding that the clinically effective antipsychotic drug CLZ, which does not produce extrapyramidal side effects, has an effect very different from that observed with the other antipsychotic drugs. Thus, although repeated treatment with CLZ reduced the number of spontaneously active DA neurons encountered in AlO, it increased the number of DA cells spontaneously firing in A9. Moreover, this increase in the number of active DA neurons in A9 was no different from the effects observed 1 hr after acute CLZ treatment. Although the dose of CLZ employed in this study was high (25 mg/kg), the differential effect of chronic treatment with this drug on A9 and A10 DA cells cannot be attributed to the use of a relatively high dose because identical results were obtained with the repeated administration of 10 mg/kg/day for 21 days (N = 12) (L. A. Chiodo and B. S. Bunney, unpublished data) .
At the present time, it is not clear why repeated CLZ treatment is unable to induce depolarization inactivation in A9 neurons while all other neuroleptics tested did. There are several possible explanations. First, it has been suggested on the basis of both receptor binding (Snyder et al., 1974; Miller and Hiley, 1974; Pelham and Munsat, 1979; Racagni et al., 1980) and DA turnover studies (Anden and Stock, 1973; Marco et al., 1976 ) that CLZ does not cause extrapyramidal side effects because it also exerts an anticholinergic action within the brain. However, in viva physiological studies have shown that CLZ, even at relatively high doses, is a weak antagonist of the acetylcholine-induced excitation of neurons located in the zona reticulata of the substantia nigra (Aghajanian and Bunney, 1974) . It is not known at present whether CLZ is also a weak antagonist of the physiological effects of acetylcholine in other relevant aminergic regions (e.g., striatum). Second, it has been shown that CLZ is also an a-noradrenergic (NE) receptor antagonist (Bartholini et al., 1972; Burki et al., 1974; McMillen and Shore, 1978; Souto et al., 1979) which might, in part, account for its differential effect on A9 neurons. Supporting this hypothesis is the finding that the cu-NE antagonist piperoxane has been shown to alter the activity of A9 neurons indirectly through the serotonergic dorsal raphe system (Bunney and DeRiemer, 1982) . Third, it is possible that CLZ affects postsynaptic DA receptors differently in striatal and limbic areas. For example, it has been found that intravenous CLZ blocks DA inhibitory effects in the nucleus accumbens (Aghajanian and Bunney, 1974) but not in the caudate nucleus (Bunney and Aghajanian, 1978) . It has also been reported that CLZ prevents ["HI spiperone binding in cortical and limbic regions but not in the striatum (Kohler et al., 1981) .
This inability to block DA effects in the caudate nucleus would suggest that CLZ may be unable to affect striatonigral and pallidonigral feedback pathway function. Such a lack of action might underlie its inability to induce depolarization inactivation in A9 cells. Our observations, that the destruction of these long-loop feedback pathways with intrastriatal kainic acid injections (Bunney and Grace, 1978) or transections blocks and reverses the ability of repeated HAL and CPZ administration, respectively, to decrease the number of active DA neurons encountered in A9, indirectly support this hypothesis. However, further studies testing these and other possibilities are obviously necessary if we are to understand the neuronal mechanisms underlying the lack of depolarization inactivation of A9 DA neurons associated with chronic CLZ treatment.
It has been well established, biochemically, that the neuroleptics l-SLP, CPZ, and HAL (as well as a variety of others) acutely increase DA turnover in lower mammals (Carlsson and Lindqvist, 1963; Anden and Stock, 1973; Nyback et al., 1967; Nyback and Sedvall, 1970; Asper et al., 1973; Bowers and Rozitis, 1974; Scatton, 1977; Bannon et al., 198213, 1983) as well as in human and nonhuman primates (Post and Goodwin, 1975; Roth et al., 1980; Bacopoulos et al., 1982) . As proposed earlier (Bunney and Grace, 1978) , our present data suggest that acute antipsychotic drug treatment increases DA release, at least in part, by activating normally silent DA neurons and increasing the activity of those DA neurons already firing (Bunney et al., 1973; Bunney, 1979) . However, after repeated treatment tolerance develops to the biochemical effects of acute antipsychotic drug administration (Asper et al., 1973; Bowers and Rozitis, 1974; Post and Goodwin, 1975; Gerlach et al., 1975; Scatton, 1977; Bacopoulos et al., 1982) . Various hypotheses have been proposed to explain this phenomenon. Our data suggest that this effect may, in part, be related to the progressive development of depolarization inactivation of both A9 and A10 DA neurons. Thus, one might expect that with the onset of depolarization there would be a concurrent reduction in the amount of DA released from the nerve terminal. When all of the DA neurons projecting to a given area have reached a state of depolarization inactivation, any release which still occurred would be greatly reduced and no longer impulse dependent.
Further support for the hypothesis that biochemical tolerance may be related to depolarization inactivation comes from a parallel between biochemical findings and our electrophysiological results with acute and chronic CLZ. Thus, it has been reported that DA neurons innervating limbic regions (predominantly A10 cells) develop tolerance to repeated CLZ administration whereas those projecting to the striatum (A9 cells) do not (Burki et al., 1974; Waldmeier and Maitre, 1976; Racagni et al., 1980) . Our observations that repeated CLZ treatment resulted in depolarization block of A10 but not A9 DA cells could be the mechanism underlying this finding. However, arguing against our hypothesized relationship between the development of depolarization inactivation and biochemical tolerance is the report that biochemical tolerance to neuroleptics will occur in animals with kainic acid lesions of the striatum (DiChiara et al., 1977a , Scatton, 1980 The present study indicates that mesocortical DA neurons projecting to the prefrontal cortex do not go into depolarization inactivation as a result of chronic neuroleptic treatment. This is in agreement with biochemical findings in lower mammals. (Scatton, 1977; Bannon et al., 1982a) , as well as human and nonhuman primates (Roth et al., 1980; Bacopoulos et al., 1982) , which demonstrate that both the increase in DA metabolites and the activation of tyrosine hydroxylase normally observed in the prefrontal cortex after acute neuroleptic treatment do not abate during chronic administration. It is these same DA neurons which lack autoreceptors (Bannon et al., 1981 ; L. A. Chiodo, M. J. Bannon, R. H. Roth, and B. S. Bunney, unpublished data). However, any causal relationship between this fact and the inability of these neurons to develop depolarization block remains obscure at this time. Moreover, the possibility that a higher dose or longer treatment might ultimately result in depolarization inactivation remains to be determined. Do the sequences of electrophysiological events described above, which are associated with repeated neuroleptic treatment, underlie any of the time-dependent effects of antipsychotic drug administration observed clinically (Bunney and Grace, 1978) ? One possibly related clinical action of these drugs might be their Parkinson-like side effects which can take days or weeks to develop fully (Klein et al., 1980; Jeste and Wyatt, 1982) . The onset of these side effects cannot correspond to the blockade of postsynaptic DA receptors by antipsychotic drugs since this is known to occur immediately after acute administration. The lack of their development acutely might be explained by two facts: (1) neuroleptics are competitive inhibitors for DA receptors, and (2) an increased release of DA would occur acutely. The latter would result from: (1) the increase in the firing rate of spontaneously active DA cells, (2) the activation of normally silent DA cells, and (3) the blockade of DA nerve terminal autoreceptors (Kehr et al., 1972; Roth et al., 1975) . All three actions would serve to reduce the postsynaptic receptor-blocking effects of these compounds by greately increasing the number of dopamine molecules within the synapse which would be available to compete with neuroleptic molecules for the DA receptor. Furthermore, it has recently been demonstrated that a 70% depletion of striatal DA must occur before Parkinson-like symptoms become manifest (Javoy-Agid et al., 1981) . On the other hand, the hypothesized decrease in DA release associated with the time-dependent development of depolarization inactivation would, over time, reduce this initial competition between DA and neuroleptic molecules for postsynaptic receptors. This would result in a progressively more effective blockade by these compounds and finally the emergence of extrapyramidal side effects. Such a sequence of events would also fit with the inability of CLZ to induce Parkinsonlike side effects. Thus, since biochemical results (Burki et al., 1974; Waldmeier and Maitre, 1976; Racagni et al., 1980) and our present electrophysiological findings demonstrate no difference between acute and repeated CLZ treatment, DA might continue to be released and, therefore, be available to compete with CLZ for postsynaptic DA receptors in the striatum.
The development of depolarization inactivation in A9 could also contribute to the development of tardive dyskinesia. The reduced availability of DA at the synapse (i.e., enhanced receptor blockade) would serve to potentiate the neuroleptic-induced sensitization of postsynaptic DA receptors which is generally believed to be a major factor in the development of tardive dyskinesia (Klawans, 1976; Baldessarini and Tarsy, 1976, 1980; Jeste and Wyatt, 1982) . One could speculate that the inability of CLZ to induce depolarization block in A9 would reduce the development of DA receptor supersensitivity in the striatum. Receptor-binding studies support this notion since repeated CLZ treatment, unlike treatment with classical neuroleptics, has been reported not to increase postsynaptic DA receptor binding (Kobayashi et al., 1978; Creese and Snyder, 1980) . These atypical actions of CLZ in the nigrostriatal DA system may, in part, explain why CLZ does not cause tardive dyskinesia even after long-term treatment. If correct, this hypoth-
